Imapct of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
基本信息
- 批准号:7095258
- 负责人:
- 金额:$ 12.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-08-15 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Renal cell carcinoma (RCC) takes 12,000 American lives each year. Existing systemic therapies are curative in fewer than 10% of patients, and targeted therapeutic approaches are needed. Loss of the von Hippel Lindau (VHL) tumor suppressor is an early event in the development of most clear cell RCC, and preliminary studies have indicated that a critical function of VHL is ubiquitin-mediated degradation of hypoxia inducible factor alpha (HIF-alpha). HIF-alpha stability and transactivation are regulated by hypoxia and redox signaling by two independent mechanisms that involve binding of VHL and the transcriptional co-activator CBP/p300. A novel kidney-specific, superoxide-producing NAD(P)H oxidase, Renox, was recently described and implicated in oxygen sensing for maintenance of oxygen homeostasis via secretion of erythropoeitin. This exclusive renal function is known to require HIF transcriptional activation. The hypothesis of this proposal is that Renox-mediated accumulation of reactive oxygen species (ROS) within the renal cell influences activation of HIF-( leading to malignant transformation in the absence of functional VHL. There are three major aims of this work. The first is to determine the effect of Renox and ROS upon HIF-alpha regulation and activity. A second aim is to determine the effect of redox signaling upon HIF-alpha post-translational modification. The final aim is to specifically inhibit Renox function to determine its effects on the tumorigenic phenotype of renal cell carcinoma. Although this work is of high relevance to renal carcinogenesis, its has broader implications in the areas of renal microenvironment, oxidative stress in disease states, and general renal physiology. The candidate is a urologist with expertise in the area of molecular genetics of kidney cancer. She recently completed a research fellowship in urologic oncology at the National Cancer Institute. The candidate seeks to establish a career as an independent physician-scientist in an academic setting where 75% of her time is devoted to the laboratory and 25% to teaching and.clinical work. This will be achieved by a comprehensive program to acquire both technical and intellectual skills under the guidance of two distinguished and outstanding mentors, Shuk Mei Ho and Gary Stein, and to draw upon the scientific strengths of a number of investigators within the UMass Medical School community. This will provide an excellent environment for completion of this project and a basis for transition to independent investigator.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JODI Kathleen MARANCHIE其他文献
JODI Kathleen MARANCHIE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JODI Kathleen MARANCHIE', 18)}}的其他基金
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
靶向 RCC 血管的疫苗促进 TME 正常化并增强 TIL 招募
- 批准号:
10295913 - 财政年份:2021
- 资助金额:
$ 12.62万 - 项目类别:
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
靶向 RCC 血管的疫苗促进 TME 正常化并增强 TIL 招募
- 批准号:
10682463 - 财政年份:2021
- 资助金额:
$ 12.62万 - 项目类别:
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
靶向 RCC 血管的疫苗促进 TME 正常化并增强 TIL 招募
- 批准号:
10491108 - 财政年份:2021
- 资助金额:
$ 12.62万 - 项目类别:
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
用于膀胱癌分期的膀胱壁虚拟组织学
- 批准号:
10044470 - 财政年份:2020
- 资助金额:
$ 12.62万 - 项目类别:
Imapct of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
- 批准号:
7253556 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Imapct of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
- 批准号:
6899282 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Impact of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
- 批准号:
7285579 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Impact of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
- 批准号:
6675234 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Imapct of Renox on HIF-alpha in Renal Cancer
Renox 对肾癌 HIF-α 的影响
- 批准号:
6788062 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
相似海外基金
Metabolomic Analysis of Redox control in Mycobacterium tuberculosis persisters
结核分枝杆菌持续存在氧化还原控制的代谢组学分析
- 批准号:
7980241 - 财政年份:2010
- 资助金额:
$ 12.62万 - 项目类别:
Metabolomic Analysis of Redox control in Mycobacterium tuberculosis persisters
结核分枝杆菌持续存在氧化还原控制的代谢组学分析
- 批准号:
8075073 - 财政年份:2010
- 资助金额:
$ 12.62万 - 项目类别:
Lycopene Chemoprevention of Lung Cancer in Ferret
番茄红素对雪貂肺癌的化学预防作用
- 批准号:
7036073 - 财政年份:2006
- 资助金额:
$ 12.62万 - 项目类别:
MRS Detects Metabolic Dysfunction after Brain Injury
MRS 检测脑损伤后代谢功能障碍
- 批准号:
7029334 - 财政年份:2006
- 资助金额:
$ 12.62万 - 项目类别:
Modes of Energy Production and clk-1 Life Extension
能量产生模式和 clk-1 寿命延长
- 批准号:
7040276 - 财政年份:2006
- 资助金额:
$ 12.62万 - 项目类别:
Oxidant Stress and Thiol Redox State in Endothelial Cells
内皮细胞中的氧化应激和硫醇氧化还原态
- 批准号:
7137155 - 财政年份:2005
- 资助金额:
$ 12.62万 - 项目类别:
Metabolic Neuroprotection:Creatine Supplementation in Human Brain
代谢神经保护:人脑肌酸补充
- 批准号:
7226130 - 财政年份:2005
- 资助金额:
$ 12.62万 - 项目类别:
Novel methodology for studing oxidative metabolism
研究氧化代谢的新方法
- 批准号:
7014050 - 财政年份:2005
- 资助金额:
$ 12.62万 - 项目类别:














{{item.name}}会员




